Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer

Clinical Cancer Research

Volumn 9, Issue 2, 2003, Pages 571-579

  Santimaria, Monica ^a   Moscatelli, Giovanni ^a   Viale, Giuseppe L ^b   Giovannoni, Leonardo ^c   Neri, Giovanni ^c   Viti, Francesca ^c   Leprini, Alessandra ^c   Borsi, Laura ^d   Castellani, Patrizia ^d   Zardi, Luciano ^d   Neri, Dario ^e   Riva, Pietro ^a,f  

^a BUFALINI HOSPITAL   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c Philogen SpA   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

^e ETH ZURICH   (Switzerland)

^f ISTITUTO ONCOLOGICO ROMAGNOLO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; FIBRONECTIN; IODINE 123; L19 ANTIBODY; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BRAIN TUMOR; CANCER; CANCER DIAGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG TARGETING; DRUG TOLERABILITY; DRUG URINE LEVEL; HUMAN; IMMUNOSCINTIGRAPHY; ISOTOPE LABELING; LIVER METASTASIS; LUNG CANCER; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; RADIOIODINATION; SIDE EFFECT; TUMOR VASCULARIZATION;

ADULT; AGED; BIOLOGICAL MARKERS; BRAIN NEOPLASMS; COLORECTAL NEOPLASMS; DIMERIZATION; FIBRONECTINS; HUMANS; IMMUNOHISTOCHEMISTRY; IODINE RADIOISOTOPES; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RADIOIMMUNODETECTION;

EID: 0037314650     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Folkman, J. Angiogenesis in cancer, vascular, rheumathoid and other disease. Nat. Med., 1: 27-31, 1995.
2. Carmeliet, P. Mechanisms of angiogenesis and arteriogenesis, Nat. Med., 6: 389-395, 2000.
3. Ferrara, N., and Alitalo, K. Clinical applications of angiogenic growth factors and their inhibitors. Nat. Med., 5: 1359-1364, 1999.
4. Hanahan, D., and Folkman, J., Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 86: 353-564, 1998.
5. Thorpe, P. E., and Ran, S., Tumor Infarction by Targeting Tissue Factor to Tumor Vasculature. Cancer J., 66: 237-244, 2000.
6. Halin, C., Zardi, L., and Neri, D. Antibody-based targeting of angiogenesis. News Physiol. Sci., 16: 191-194, 2001.
7. Weber, W. A., Haubner, R., Vabuliene, E., Kuhnast, B., Wester, H. J., and Schwaiger, M. Tumor angiogenesis targeting using imaging agents. Q. J. Nucl. Med., 45: 179-182, 2001.
8. Castellani, P., Viale, G., Dorcaratto, A., Nicolo, G., Kaczmarek, J., Querze, G., and Zardi. L The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. Int. J. Cancer, 59: 612-618, 1994.
9. Haubner, R., Wester, H. J., Weber, W. A., Mang, C., Ziegler, S. I., Goodman, S. L., Senekowitsch-Schmidtke, R., Kessler, H., and Schwaiger, M. Noninvasive imaging of α(v) β3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res., 61: 1781-1785, 2001.
10. Sipkins, D. A., Cheresh, D. A., Kazemi, M. R., Nevin, L. M., Bednarski, M. D., and Li, K. C. Detection of tumor angiogenesis in vivo by αVβ3-targeted magnetic resonance imaging. Nat. Med., 4: 623-626, 1998.
11. Posey, J. A., Khazaeli, M. B., DelGrosso, A., Saleh, M. N., Lin, C. Y., Huse, W., and LoBuglio, A. F A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti α v β 3) antibody in patients with metastatic cancer. Cancer Biother. Radiopharm., 16: 125-132, 2001.
12. Halin, C., and Neri, D. Antibody-based targeting of angiogenesis. Crit. Rev. Ther. Drug Carrier Syst., 18: 299-339, 2001.
13. Kaczmarek, J., Castellani. P., Nicolo', G., Spina, B., Alemanni, G., and Zardi, L. Distribution of oncofetal fibronectin isoforms in normal, hyperplastic and neoplastic human breast tissues. Int. J. Cancer, 58: 11-16, 1994.
14. Scarpino, S., Stoppacciaro, A., Pellegrini, C., Marzullo, A., Zardi, L., Tartaglia, F., Viale, G., and Ruco, L. P Expression of EDA/EDB isoforms of fibronectin in papillary carcinoma of the thyroid. J. Pathol., 188: 163-167, 1999.
15. Karelina, T. V., and Eisen, A. Z. Interstitial collagenase and the ED-B oncofetal domain of fibronectin are markers of angiogenesis in human skin tumors. Cancer. Detect. Prev., 22: 438-444, 1998.
16. Viti, F., Nilsson, F., Demartis, S., Huber, A., and Neri, D. Design and use of phage display libraries for the selection of antibodies and enzymes. Methods Enzymol., 326: 480-505, 2000.
17. Rader, C., and Barbas, C. F., III. Phage display of combinatorial antibody libraries. Curr. Opin. Biotechnol., 8: 503-508. 1997.
18. Winter, G., Griffiths, A. D., Hawkins, R. E., and Hoogenboom, H. R. Making antibodies by phage display technology. Annu. Rev. Immunol., 12: 433-455, 1994.
19. Hoogenboom, H. R., Henderikx, P., and de Haard, H. Creating and engineering human antibodies for immunotherapy. Adv. Drug Deliv. Res., 31., 5-31, 1998.
20. Carnemolla, B., Neri, D., Castellani, P., Leprini, A., Neri, G., Pini, A., Winter, G., and Zardi, L. Phage antibodies with pan-species recognition of the oncofoetal angiogenesis marker fibronectin ED-B domain. Int. J. Cancer. 68: 397-405, 1996.
21. Pini, A., Viti, F., Santucci, A., Carnemolla, B., Zardi, L., Neri, P., and Neri, D. Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J. Biol. Chem., 273: 21769-21776, 1998.
22. Giovannoni, L., Viti, F., Zardi, L., and Neri, D. Isolation of antiangiogenesis antibodies from a large combinatorial repertoire by colony filter screening. Nucleic Acids Res., 29: e27, 2001.
23. Neri, D., Carnemolla, B., Nissim, A., Leprini, A., Querze, G., Balza, E., Pini, A., Tarli, L., Halin, C., Neri, P., Zardi, L., and Winter, G. Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform. Nat. Biotechnol., 15: 1271-1275, 1997.
24. Viti, F., Tarli, L., Giovannoni. L., Zardi, L., and Neri, D. Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis. Cancer Res., 59: 347-352, 1999.
25. Tarli, L., Balza, E., Viti, F., Borsi, L., Castellani, P., Berndorff, D., Dinkelborg, L., Neri, D., and Zardi. L A high-affinity human antibody that targets tumoral blood vessels. Blood, 94: 192-198. 1999.
26. Demartis, S., Tarli, L., Borsi, L., Zardi, L., and Neri, D. In vivo targeting of tumour neo-vasculature by a radiohalogenated human antibody fragment specific for the ED-B domain of fibronectin. Eur. J. Nucl. Med., 28: 534-539, 2001.
27. Birchler, M., Viti, F., Zardi, L., Spiess, B., and Neri, D. Selective targeting and photocoagulation of ocular angiogenesis mediated by a phage-derived recombinant antibody. Nat. Biotechnol., 17: 984-988, 1999.
28. Nilsson, F., Koshmehl, H., Zardi, L., and Neri, D. Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumours in mice. Cancer Res., 61: 711-716, 2001.
29. Carnemolla, B., Borsi, L., Balza, E., Castellani, P., Meazza, R., Berndt, A., Ferrini, S., Kosmehl, H., Neri, D., and Zardi, L. Enhancement of the anti-tumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood, 99: 1659-1665, 2002.
30. Halin, C., Rondini, S., Nilsson, F., Berndt, A., Kosmehl, H., Zardi, L., and Neri. D. Enhancement of the anti-tumor activity of interleukin-12 by targeted delivery to neo-vasculature. Nat. Biotechnol., 20: 264-269, 2002.
31. Begent, R. H., Verhaar, M. J., Chester. K. A., Casey, J. L., Green, A. J., Napier, M. P., Hope-Stone, L. D., Cushen, N., Keep, P. A., Johnson, C. J., Hawkins, R. E., Hilson, A. J., and Robson, L. Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. Nat. Med., 2: 979-984, 1996.
32. Begent, R. H., Chester, K. A., Connors, T., Crowther, D., Fox, B., Griffiths, E., Hince, T. A., Ledermann, J. A., McVie, J. G., Minor, P., and et al. Cancer Res. Campaign operation manual for control recommendations for products derived from recombinant DNA technology prepared for investigational administration to patients with cancer in phase I trials. Eur. J. Cancer, 29A: 1907-1910, 1993.
33. Mayer, A., Chester, K. A., Bhatia, J., Pedley, R. B., Read, D. A., Boxer, G. M., and Begent, R. H. Exemplifying guidelines for preparation of recombinant DNA products in phase 1 trials in cancer: preparation of a genetically engineered anti-CEA single chain Fv antibody. Eur. J. Cancer, 34: 968-976, 1998.
34. Riva, P., Franceschi, G., Frattarelli, M., Lazzari, S., Riva, N., Giuliani, G., Casi, M., Sarti, G., Guiducci, G., Giorgetti, G., Gentile, R., Santimaria, M., Jermann, E., and Maeke, H. R. Loco-regional radioimmunotherapy of high-grade malignant gliomas using specific monoclonal antibodies labeled with 90Y: a phase I study. Clin. Cancer Res., 5(10 Suppl): 3275s-3280s, 1999.
35. Kosmehl, H., Berndt, A., Strassburger, S., Borsi, L., Rousselle, P., Mandel, U., Hyckel, P., Zardi, L., and Katenkamp, D. D. Distribution of laminin and fibronectin isoforms in oral mucosa and oral squamous cell carcinoma. Br. J. Cancer., 81: 1071-1079, 1999.
36. Berndt, A., Borsi, L., Luo, X., Zardi, L., Katenkamp, D., and Kosmehl, H. Evidence of ED-B+ fibronectin synthesis in human tissues by non-radioactive RNA in situ hybridization. Investigations on carcinoma (oral squamous cell and breast carcinoma), chronic inflammation (rheumatoid synovitis) and fibromatosis (Morbus Dupuytren). Histochem. Cell Biol., 109: 249-55, 1998.
37. Castellani, P., Borsi, L., Carnemolla, B., Birò, A., Dorcaratto, A., Viale, G. L., Neri, D., and Zardi, L. Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin. Am. J. Pathol., 161: 1695-1700, 2002.
38. Operation manual for control of production, preclinical toxicology and phase I trials of antitumour antibodies and drug antibodies conjugates. Prepared by a Joint Committee of the Cancer Research Campaign National Institute for Biological Standards and Control. Br. J. Cancer, 54: 557-668, 1986.
39. Del Sole, A., Falini, A., Ravasi, L., Ottobrini, L., De Marchis, D., Bombardieri, E., and Lucignani, G. Anatomical and biochemical investigation of primary brain tumours. Eur. J. Nucl. Med., 28: 1851-1872, 2001.
40. Bosslet, K., Straub, R., Blumrich, M., Czech, J., Gerken, M., Sperker, B., Kroemer, H. K., Gesson, J. P., Koch, M., and Monneret, C. Elucidation of the mechanism enabling tumor selective prodrug monotherapy. Cancer Res., 58: 1195-201, 1998.
41. Browder, T., Butterfield, C. E., Kraling, B. M., Shi, B., Marshall, B., O'Reilly, M. S., and Folkman, J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res., 60: 1878-1886, 2000.
42. Klement, G., Huang, P., Mayer, B., Green, S. K., Man, S., Bohlen, P., Hicklin, D., and Kerbel, R. S. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin. Cancer Res., 8: 221-232, 2002.
43. Beekman, F. J., Kamphuis, C., King, M. A., van Rijk, P. P., and Viergever, M. A. Improvement of image resolution and quantitative accuracy in clinical Single Photon Emission Computed Tomography. Comput. Med. Imaging Graph., 25: 135-146, 2001.
44. Liberatore, M., Neri, D., Neri, G., Pini, A., Iurilli, A. P., Ponzo, F., Spampinato, G., Padula, F., Pala, A., and Colella, A. C. Efficient one-step direct labelling of recombinant antibodies with technetium-99m. Eur. J. Nucl. Med., 22: 1326-1329, 1995.
45. Verhaar, M. J., Keep, P. A., Hawkins, R. E., Robson, L., Casey, J. L., Pedley, B., Boden, J. A., Begent, R. H., and Chester, K. A. Technetium-99m radiolabeling using a phage-derived single-chain Fv with a C-terminal cysteine. J. Nucl. Med., 37: 868-872, 1996.